GSK challenges Cabilly patent

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) filed suit against Genentech Inc. and the City of Hope (Duarte, Calif.) in the U.S. District Court for the Southern District of Florida challenging the validity of the Cabilly II patent (U.S. Patent No. 6,331,415) covering methods of antibody production. GSK is seeking declaratory judgment that the patent is invalid, unenforceable and not infringed by Arzerra ofatumumab from GSK and Genmab A/S (CSE:GEN). The human mAb against CD20 is under FDA review for refractory chronic lymphocytic leukemia with an Oct. 31 PDUFA date. ...